Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors
A new cell therapy startup from an immunotherapy pioneer raises $175M in KRAS quest
Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field
Affini-T Therapeutics CEO Jak Knowles, M.D., is no stranger to the kind of startups that draw early capital, having once been vice president of venture investments for Bayer’s VC arm, Leaps by Bayer. But now, he’s the one asking for money, and his former employer is ready to dole it out. Led by Vida Ventures […]
Affini-T Therapeutics launches with $175 million for cancer treatments
The startup, based in Boston and Seattle, will make T cell therapies for infamously tough-to-treat conditions.
Vida, Bayer throw weight behind $175M T-cell startup
Affini-T Therapeutics has formally launched with $175 million in venture capital, one clinical-stage drug licensed from Fred Hutch and two more solid tumor-targeting drugs that should enter the clinic next year.
See the 24-slide pitch deck a new biotech startup just used to raise $175 million to develop the next cancer breakthrough
New Cell Therapy Player Makes Public Debut at JPM
Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients. First reported by Geek Wire, Affini-T, based in Boston, is harnessing T cell […]
Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer
A new cell therapy company is on the block, propelled by powerhouse scientific co-founders from Fred Hutchinson Cancer Research Center with years of experience investigating how to harness the immune system to treat cancer. Affini-T Therapeutics, which emerged Wednesday in a presentation at the J.P. Morgan Health Care Conference, is headquartered in Boston and has […]
A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
There are two things Phil Greenberg, the head of immunology at Fred Hutchinson Cancer Research Center, is especially well-known for: a characteristic wiry gray mop of hair and wide glasses, and a rock-solid reputation as one of the leading researchers in cancer immunotherapy. Greenberg was behind some of the key scientific advances that led to […]
